As of Mar 27
| +0.26 / +1.76%|
The 9 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 15.00, with a high estimate of 17.00 and a low estimate of 7.00. The median estimate represents a -0.46% decrease from the last price of 15.07.
The current consensus among 9 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.